Compugen (NASDAQ:CGEN – Get Free Report) posted its quarterly earnings results on Tuesday. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.14), Zacks reports. The firm had revenue of $1.47 million for the quarter, compared to analysts’ expectations of $17.47 million. Compugen had a net margin of 2.67% and a return on equity of 2.62%.
Compugen Stock Up 7.7 %
Shares of NASDAQ CGEN opened at $1.81 on Thursday. Compugen has a fifty-two week low of $1.35 and a fifty-two week high of $3.03. The business has a 50 day moving average price of $2.04 and a two-hundred day moving average price of $1.84. The firm has a market cap of $161.52 million, a PE ratio of 90.50 and a beta of 2.98.
Wall Street Analyst Weigh In
Several research analysts recently commented on the stock. StockNews.com lowered shares of Compugen from a “buy” rating to a “hold” rating in a report on Wednesday. Oppenheimer started coverage on shares of Compugen in a research note on Monday, January 13th. They issued an “outperform” rating and a $4.00 target price on the stock.
Compugen Company Profile
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.
Featured Stories
- Five stocks we like better than Compugen
- Do ETFs Pay Dividends? What You Need to Know
- Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors
- What is Put Option Volume?
- Why Now Might Be the Best Time to Buy Target Stock
- Upcoming IPO Stock Lockup Period, Explained
- Why TJX Companies Belongs in Every Dividend Growth Portfolio
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.
